Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting
- First Online:
- Cite this article as:
- González-Martín, A., Toledo, G. & Chiva, L. Clin Transl Oncol (2010) 12: 418. doi:10.1007/s12094-010-0529-1
Epithelial ovarian carcinoma is still the most common cause of death from gynaecological cancer in USA and western Europe. The optimal therapy of epithelial ovarian carcinoma requires participation of a multidisciplinary team — from diagnosis through the entire natural history of each individual patient. Only 20–30% of patients are diagnosed at the initial stage, when appropriate staging surgery in combination with adjuvant chemotherapy for high-risk patients can be curative. Treating patients with advanced disease consists of a staging surgery with maximum cytoreductive effort, followed by chemotherapy with a combination of taxane and carboplatin. Unfortunately, the majority of patients with advanced disease will relapse and become candidates for therapy that comprises individualised chemotherapy, and surgery in selected cases. For this reason, there is still a need for new treatments and strategies in the first-line setting.